Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Com... ( -Study Published in Neurogastroen...)

Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications

Date:10/25/2007

-Study Published in Neurogastroenterology and Motility-

MONTVALE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI) announced today the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced glycated end-products (AGEs) and restore neuronal nitric oxide synthase (nNOS) activity in rats with diabetes. Loss of gastrointestinal nNOS activity is one of the major putative mechanisms for the development of diabetic complications involving the gut including gastroparesis and intestinal dysfunction and has been the subject of both intense investigation and thorough review(1). Diabetic gastroparesis is a motility disorder in which the stomach takes too long to empty its contents. It is a disease of significant unmet medical need, as no pharmaceutical products are approved for the treatment of this condition, which afflicts one million type 1 and type 2 diabetic patients in the U.S. and many more worldwide.

Pankaj J. Pasricha, M.D., Ph.D., Professor and Chief, Division of Gastroenterology & Hepatology at Stanford University School of Medicine, and colleagues; Dr. Prince VS Jeyabal, Dr. Raj Kumar, Dr. Pandu RR Gangula, Dr. Mary-Adelaide Micci; from the University of Texas Medical Branch authored the paper, which was published in the October 2007 issue of Neurogastroenterology and Motility. Dr. Pasricha is also Chairman of the NIH-funded Diabetic Gastroparesis Consortium, which has a mandate to better characterize the underlying biology and develop therapeutic interventions for patients with diabetic gastroparesis.

In this study, Dr. Pasricha examined the expression of duodenal nNOS and the role of AGE and RAGE (recep
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

Post Your Comments:

(Date:11/29/2009)...wire/ -- A large proportion of patients who underg...e unindicated and unnecessary additional image acq...exposure, according to a study presented today at ...North America (RSNA). ,, "It is the responsibil...tion to ensure that the dosage is as low as reason...

(Date:11/29/2009)...Newswire/ -- Royal Philips Electronics ( PHG, AEX:...need by showing its portfolio of products designed...al meeting of the Radiological Society of North Am...ps are several advancements and upgrades focused o...streamlining workflow to expand upon clinical capa...

(Date:11/29/2009)...ewswire/ -- FUJIFILM Medical Systems USA, Inc., th...FFDM) with over 7,000 installations, is pleased to...me in the US. The Aspire HD combines the use of a...generation detector technology and the smallest pi... resolution at a reduced dose for the patient. Th...

Breaking Medicine Technology:Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 2 Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients 3 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 2 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 3 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 4 Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients 5 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 2 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 3 FUJIFILM's DR-based FFDM System Makes US Debut at RSNA 4 Intralase 26amp 3B 238220 3BBladeless 26amp 3B 238221 3B Lasik Gains Popularity in the Raleigh NC Area 49584 1 Intralase 26amp 3B 238220 3BBladeless 26amp 3B 238221 3B Lasik Gains Popularity in the Raleigh NC Area 49584 2 U S Army Increases Medical and Dental School Benefits 49582 1 U S Army Increases Medical and Dental School Benefits 49582 2 U S Army Increases Medical and Dental School Benefits 49582 3 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 1 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 2 BioMed Realty Trust Closes New 2418 Million Secured Loan 49580 3

[0] Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients [0] Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients [0] FUJIFILM's DR-based FFDM System Makes US Debut at RSNA

...herapeutic Proteins at Tumor,Site, ARLINGTON HEIG...eons have delivered cancer fighting proteins throu...ith a 79 percent reduction,in tumor volume, accord...onstructive Surgery(R), the official medical journ...PS). This new delivery technique, which has,yet to...

...,AZN) today announced the submission of a suppleme...and Drug Administration (FDA) for SEROQUEL XR(TM),...seek approval for the,treatment of generalized anx...anxiety effect. It is the first time approval has ... in GAD. The submission is based on a robust,clini...

Other Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2 Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7 AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8

Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

(Date:11/27/2009)...., Nov. 27 GSI Group Inc...of precision technology products and semiconductor...f the Company,s shareholders has been scheduled fo...f the meeting will be announced in due course. As...isition notice from Stephen Bershad, a holder of g...

(Date:11/27/2009)...Biotech firm Replikins Ltd. today issued its lates...ata. It shows that the lethality of the virus has...e virus,s current outbreak in the spring of 2009 t...d. 0.1). The H1N1 infectivity count, however, rema...PRWEB) November 27, 2009 -- Biotech firm Replikins...

(Date:11/27/2009)...Nov. 27 The Gymboree Cor...bert, CFO/COO, will present at the NASDAQ OMX 23rd...air Hotel in London, England, on Wednesday, Decemb...a live broadcast of The Gymboree Corporation,s pre...gymboree.com, click on "Our Company" at the bottom...

(Date:11/27/2009)...SEINE, France, Nov. 27 Team Garmin...ng team dedicated to ethical sporting and developi...nced today that it will become Team Garmin-Transit... new sponsor of the team. Transitions Optical is t...r, offering the most advanced photochromic technol...

(Date:11/27/2009)...XenaCare Holdings has announced that it has become...ne of the largest nonprofit organizations dedicate...n. , Delray Beach, FL (Vo...(OTCBB: XCHO), a company specializing in the marke...e products, has announced today that is has become...

Breaking Medicine News(10 mins):Health News:GSI Group Calls Shareholders Meeting 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4 Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4

[0] GSI Group Calls Shareholders Meeting [0] Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased [0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation

...nd New Regulations Could Hold the Key to ...ORK, Nov. 8 It is estimated that more than 1,mill...the United States in,2007. While most skin cancers...e hopeful that the recent introduction,of a new la...

...e the Effects of Stress on the Skin, Hair and ... 8 Pending job cuts at the office.,Back-to-back f.... What do,they all have in common? In a word -- st...acne, brittle nails or even hair,loss. Speaking t...

... Universities to Develop a New Thrombectomy ... ST. PAUL, Minn., Nov. 8 In a unanimous decision ... support of Governor John Hoeven,and the state,s C...tate University (NDSU) to develop and manufacture ...

...Diabetes Day, November 14,is observed every year b...,and by others with an interest in diabetes. This ...and adolescents," provides an excellent opportunit...lth (NIH), researchers at more,than 150 medical ce...

...umatic Brain Injuries: The Signature,Wounds of Ope...m, WASHINGTON, Nov. 8 - Veterans for America,s,"T...identifies a number of,interrelated trends adverse...l traumas., This report is the result of VFA,s ag...

...harma, Inc.,(Nasdaq: IDMI ) today announced its f...nded September 30, 2007. Financial information pre...Pharma and its subsidiary, IDM,S.A. Cash and cash...any,s net cash outflow from operations and,investm...

Skin Cancer Prevention Update:Feeling Stressed?North Dakota Grants Enova Medical Technologies a $2.5 Million Centers of Excellence Grant World Diabetes Day Spotlights Type 1 Diabetes Increase and World Class Response Trends in Treatment of America's Wounded Warriors IDM Pharma Reports Third Quarter 2007 Financial Results

HT-PB

CapSure Novus

Brilliant S+

RZ Series

Medicine Products:

HT-PB CapSure Novus Brilliant S+RZ Series

Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Com...( -Study Published in Neurogastroen...),Health